These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2441205)

  • 21. Role of isosorbide dinitrate in management of chronic congestive heart failure.
    Parmley WW
    Am Heart J; 1985 Jul; 110(1 Pt 2):264-8. PubMed ID: 3893081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current indications for vasodilator therapy for left ventricular failure.
    Franciosa JA
    Compr Ther; 1985 Mar; 11(3):39-46. PubMed ID: 2983926
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of vasodilator and inotropic drugs on clinical symptoms and long-term survival in chronic congestive heart failure.
    Packer M
    Eur Heart J; 1988 Jun; 9 Suppl H():105-8. PubMed ID: 2901957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination vasodilator therapy for severe chronic congestive heart failure.
    Chatterjee K; Drew D; Parmley WW; Klausner SC; Polansky J; Zacherle B
    Ann Intern Med; 1976 Oct; 85(4):467-70. PubMed ID: 823852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BiDil (isosorbide dinitrate and hydralazine hydrochloride).
    Sica DA
    Congest Heart Fail; 2006; 12(2):110-1. PubMed ID: 16596047
    [No Abstract]   [Full Text] [Related]  

  • 26. Isosorbide dinitrate and hydralazine in blacks with heart failure.
    Eisenberger AB
    N Engl J Med; 2005 Mar; 352(10):1041-3; author reply 1041-3. PubMed ID: 15761995
    [No Abstract]   [Full Text] [Related]  

  • 27. Race and a heart drug.
    Peota C
    Minn Med; 2005 Mar; 88(3):11. PubMed ID: 15852585
    [No Abstract]   [Full Text] [Related]  

  • 28. The Vasodilator-Heart Failure Trials (V-HeFT). Mechanistic data from the VA Cooperative Studies. Introduction.
    Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI1-4. PubMed ID: 8500232
    [No Abstract]   [Full Text] [Related]  

  • 29. Vasodilator treatment with isosorbide dinitrate and hydralazine in chronic heart failure.
    Massie BM; Kramer B; Shen E; Haughom F
    Br Heart J; 1981 Apr; 45(4):376-84. PubMed ID: 7225252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Isosorbide dinitrate and hydralazine in blacks with heart failure.
    Bellin EY
    N Engl J Med; 2005 Mar; 352(10):1041-3; author reply 1041-3. PubMed ID: 15761996
    [No Abstract]   [Full Text] [Related]  

  • 31. Influence of prerandomization (baseline) variables on mortality and on the reduction of mortality by enalapril. Veterans Affairs Cooperative Study on Vasodilator Therapy of Heart Failure (V-HeFT II). V-HeFT VA Cooperative Studies Group.
    Johnson G; Carson P; Francis GS; Cohn JN
    Circulation; 1993 Jun; 87(6 Suppl):VI32-9. PubMed ID: 8500237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Race, drugs, and heart failure.
    Aronow WS
    Geriatrics; 2005 Jul; 60(7):8-9. PubMed ID: 16026175
    [No Abstract]   [Full Text] [Related]  

  • 33. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial.
    Taylor AL; Ziesche S; Yancy CW; Carson P; Ferdinand K; Taylor M; Adams K; Olukotun AY; Ofili E; Tam SW; Sabolinski ML; Worcel M; Cohn JN;
    Circulation; 2007 Apr; 115(13):1747-53. PubMed ID: 17372175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of vasodilator drugs in congestive heart failure.
    Med Lett Drugs Ther; 1978 Oct; 20(20):89-91. PubMed ID: 703684
    [No Abstract]   [Full Text] [Related]  

  • 35. Results of long-term vasodilator therapy in patients with refractory congestive heart failure.
    Walsh WF; Greenberg BH
    Circulation; 1981 Sep; 64(3):499-505. PubMed ID: 7261282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of vasodilator therapy in congestive heart failure. Effects on mortality.
    Greenberg B
    Cardiol Clin; 1994 Feb; 12(1):87-99. PubMed ID: 8181028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lessons from V-HeFT: questions for V-HeFT II and the future therapy of heart failure.
    Cohn JN
    Herz; 1991 Sep; 16 Spec No 1():267-71. PubMed ID: 1820292
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial.
    Taylor AL; Sabolinski ML; Tam SW; Ziesche S; Ghali JK; Archambault WT; Worcel M; Cohn JN;
    J Card Fail; 2012 Aug; 18(8):600-6. PubMed ID: 22858074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Isosorbide dinitrate and hydralazine in blacks with heart failure.
    Moran AE; Cooper RS
    N Engl J Med; 2005 Mar; 352(10):1041-3; author reply 1041-3. PubMed ID: 15758018
    [No Abstract]   [Full Text] [Related]  

  • 40. [Vasodilator agents in chronic heart failure: which is the best option?].
    Corbalán R; Kunstmann S; Jalil J
    Rev Med Chil; 1993 Jan; 121(1):81-8. PubMed ID: 8235172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.